Nasdaq apls.

Apellis Pharmaceuticals (APLS) Wells Fargo analyst Derek Archila maintained a Buy rating on Apellis Pharmaceuticals on December 1 and set a price target of $67.00 . The company’s shares closed ...On this news, shares of Apellis fell $6.27 per share, or approximately 19.6%, from a close of $32.02 per share on July 28, 2023, to close at $25.75 per share on July 31, 2023. The case is ...APLS STOCK Price - Apellis Pharmaceuticals Inc NASDAQ USA Technical Analysis, Forecast, Important Levels, Latest News, Interactive Charts.... Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue? 3 days ago · Yahoo Finance. Apellis Pharmaceuticals' (NASDAQ:APLS) growing losses don't ...Nov 17, 2023 · Apellis Pharmaceuticals Inc (Symbol: APLS) saw options trading volume of 11,658 contracts, representing approximately 1.2 million underlying shares or approximately 61.6% of APLS's average daily ...

May 4, 2023 · Operating as a commercial-stage biopharmaceutical entity, Apellis Pharmaceuticals (NASDAQ:APLS) is dedicated to the discovery, development, and market introduction of groundbreaking therapeutic ... Find the latest analyst research for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.

Apellis Pharmaceuticals (NASDAQ:APLS) has entered into separate, privately negotiated exchange agreements with certain holders of its 3.500% Convertible Senior Notes due 2026.; Under the terms of ...

USA. Published on June 4, 2021. venBio, a Palo Alto, CA and San Francisco, CA-based closed its fourth life sciences venture capital fund, venBio Global Strategic Fund IV, LP, at approximately ...Nov 17, 2023 · Apellis Pharmaceuticals Inc (NASDAQ:APLS) showed a performance of 4.00% in past 30-days. Number of shares sold short was 16.23 million shares which calculate 7.13 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $71.19 to the stock, which implies a rise of 32.73% to its current value. Apellis Pharmaceuticals, Inc.'s APLS newly marketed product, Syfovre (pegcetacoplan injection), was approved for the treatment of geographic atrophy (GA) secondary to age-related macular ...Nov 22, 2023 · Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has dropped by -3.62 in relation to previous closing price of 49.36. Nevertheless, the company has seen a loss of -1.71% in its stock price over the last five trading days. Zacks Investment Research reported 2023-11-09 that FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating […] View today's Apellis Pharmaceuticals Inc stock price and latest APLS news and analysis. Create real-time notifications to follow any changes in the live ...

Shares of Apellis Pharmaceuticals ( APLS 6.66%) were down more than 9% on Wednesday, after falling as much as 12% earlier in the day. The company's shares fell following a short-seller report on ...

We challenge conventional thinking and always question if there's a better way. Apellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology ...

NEW YORK, Aug. 28, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) alleging ...Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) released its quarterly earnings results on Wednesday, November, 1st. The company reported ($1.17) earnings per share for the quarter, missing analysts' …14 дек. 2017 г. ... More from Nasdaq. 09:11. Abivax [ABVX] Rings the. Nasdaq Closing Bell. 1 day ago · 564 views. 00:34. As home to the world's most innovative and ...Advertisement. Apellis Pharmaceuticals Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View APLS financial statements in full.Dec 1, 2023 · The average twelve-month price prediction for Apellis Pharmaceuticals is $66.50 with a high price target of $93.00 and a low price target of $29.00. Learn more on APLS's analyst rating history. Do Wall Street analysts like Apellis Pharmaceuticals more than its competitors? JP Morgan Upgrades Apellis Pharmaceuticals (APLS) As of October 5, 2023, the average one-year price target for Apellis Pharmaceuticals is 69.00. The forecasts range from a low of 29.29 to a high ...The public float for APLS is 97.66M, and at present, short sellers hold a 16.62% of that float. On November 16, 2023, the average trading volume of APLS was 2.69M shares. APLS) stock’s latest price update. Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has plunge by 0.54relation to previous closing price of 48.14.

Apellis Pharmaceuticals (NASDAQ:APLS) dropped 8.6% amid a new short call from Citron Research. Citron claims it wouldn't be surprised if the Food and Drug Administration "steps in with a warning ...WALTHAM, Mass., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and Drug Administration (FDA) has accepted Apellis’ unsolicited major amendment to the New Drug Application (NDA) for intravitreal …WALTHAM, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced its second quarter 2020 financial results and business highlights.Apellis Pharmaceuticals, Inc. (“Apellis”) (NASDAQ:APLS) recently completed an upsized underwritten public offering of 8563830 shares of its common stock at ...Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) stock price has dropped 7.4% in the previous week, but insiders who sold US$625k in stock over the past year have had less luck. Insiders might have ...

Apellis Pharmaceuticals, Inc.'s APLS newly marketed product, Syfovre (pegcetacoplan injection), was approved for the treatment of geographic atrophy (GA) secondary to age-related macular ...

Apellis Pharmaceuticals (NASDAQ: APLS ) shares plunged Monday on the back of a short report from Citron Research, which said the "happy days are over" for the company. The short-selling firm said it has "reason to believe that CEO Cedric Francois is not being honest with Wall St. about the report cases of vasculitis" regarding the …Jan 31, 2018 · Wall Street Analysts Predict a 51.91% Upside in Apellis Pharmaceuticals, Inc. (APLS): Here's What You Should Know. (Zacks) Oct-25-23 07:00AM. Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results. Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Apellis Pharmaceuticals, Inc. (APLS). NASDAQ: APLS · IEX Real-Time Price · USD.Shares of APLS stock traded up $0.12 during trading hours on Monday, reaching $48.52. 498,084 shares of the company were exchanged, compared to its average volume of 2,676,809. Apellis ...Dec 1, 2023 · 14 analysts have issued twelve-month target prices for Apellis Pharmaceuticals' stock. Their APLS share price targets range from $29.00 to $93.00. On average, they anticipate the company's share price to reach $66.50 in the next twelve months. This suggests a possible upside of 8.0% from the stock's current price. ... Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue? 3 days ago · Yahoo Finance. Apellis Pharmaceuticals' (NASDAQ:APLS) growing losses don't ...

21 февр. 2023 г. ... On today's stock market, APLS stock surged 5.4% to close at 58.50. ... *Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices ...

A number of firms have modified their ratings and price targets on shares of Apellis Pharmaceuticals (NASDAQ: APLS) recently: 11/9/2023 – Apellis Pharmaceuticals is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “buy” rating and a $74.00 price target on the stock. 11/2/2023 – Apellis Pharmaceuticals had its price target […]

Apr 7, 2023 · The firm decreased its portfolio allocation in APLS by 48.09% over the last quarter. GSAOX - Goldman Sachs Small Cap Growth Insights Fund holds 13K shares representing 0.01% ownership of the company. Apellis Pharmaceuticals, Inc. Common Stock (APLS) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets. CRESTWOOD, Ky. and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...Nov 4, 2023 · WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 3 years of continuous treatment with ... Find the latest analyst research for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing ...Citi analyst Yigal Nochomovitz maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) on December 1 and set a price target of …If you want to know who really controls Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as ...Rost-9D/iStock via Getty Images. Apellis Pharmaceuticals (NASDAQ:APLS) and Swedish Orphan Biovitrum ((Sobi)) announce that the CHMP of the EMA has adopted a positive opinion recommending the ...WALTHAM, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced its second quarter 2020 financial results and business highlights.

Number of Hedge Fund Shareholders: 36. The number of hedge funds long Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has ticked up steadily over each of the past four quarters, more than doubling ...Nov 20, 2023 · Shares of NASDAQ APLS opened at $49.10 on Friday. The stock has a market cap of $5.82 billion, a P/E ratio of -9.35 and a beta of 0.97. The company has a current ratio of 4.29, a quick ratio of 3.76 and a debt-to-equity ratio of 0.40. Apellis Pharmaceuticals has a 12-month low of $19.83 and a 12-month high of $94.75. WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...Follow. WALTHAM, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that four oral ...Instagram:https://instagram. top gainers today stockscgc stock forecastarrstockinvesco db us dollar index bullish fund Aug 31, 2023 · Fintel reports that on September 15, 2023, Wells Fargo upgraded their outlook for Apellis Pharmaceuticals (NASDAQ:APLS) from Equal-Weight to Overweight.. Analyst Price Forecast Suggests 53.76% ... e mini dowhome insurance companies that allow rottweilers With a volume of 1,248,030, the price of APLS is up 1.39% at $51.0. RSI indicators hint that the underlying stock may be approaching overbought. Next earnings … lhyox WALTHAM Mass., and CRESTWOOD, Ky., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...Nov 1, 2023 · The firm increased its portfolio allocation in APLS by 653.58% over the last quarter. VGHCX - Vanguard Health Care Fund Investor Shares holds 5,895K shares representing 5.01% ownership of the company. WALTHAM, Mass., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and Drug Administration (FDA) has accepted Apellis’ unsolicited major amendment to the New Drug Application (NDA) for intravitreal …